Aragon Pharmaceuticals, Inc.

ACTIVE

10990 Wilshire Blvd Ste 300, Los Angeles, California, United Stateswww.aragonpharmaceuticals.comSubsidiary11–50 employeesEstablished: 2009-01-01

Part of 强生

Clinical Trials

20 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2009

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

68.8%

Phase 3

15.6%

Phase 2

3.1%

Trial Status Distribution

Active, not recruiting

62.5%

Completed

31.3%

Recruiting

3.1%

Unknown

3.1%

Clinical Trials

Trials sponsored by this organization (32)

A Study to Evaluate the Effect of Multiple Doses of JNJ-56021927 on the Pharmacokinetics of Multiple Cytochrome P450 and Transporter Substrates in Participants With Castration-Resistant Prostate Cancer

Phase 1

Active, not recruiting

interventional

Feb 201623 participants

A JNJ-56021927 (ARN-509; Apalutamide) QT/QTc Study

Phase 1

Completed

interventional

Dec 201545 participants

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Phase 3

Active, not recruiting

interventional

Nov 20151,052 participants

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3

Active, not recruiting

interventional

Nov 20151,503 participants

A Study to Evaluate the Pharmacokinetics of JNJ-56021927 in Participants With Mild or Moderate Hepatic Impairment Compared With Participants With Normal Hepatic Function

Phase 1

Completed

interventional

Aug 201524 participants

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3

Active, not recruiting

interventional

Nov 2014982 participants

A Clinical study to assess the safety and effectiveness of ARN-509 in men with Castration-Resistant Prostate Cancer (prostate cancer not responsive to castration treatment)

Phase 1

Active, not recruiting

Oct 20141,200 participants

Study to Assess Drug-Drug Interaction Between Itraconazole or Gemfibrozil and JNJ-56021927

Phase 1

Completed

interventional

Sep 201445 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations